Grufity logoGrufity logo

Replimune Group Inc Stock Research

REPL

25.89USD-0.24(-0.92%)Market Closed

Market Summary

USD25.89-0.24
Market Closed
-0.92%

REPL Stock Price

REPL RSI Chart

REPL Valuation

Market Cap

1.3B

Price/Earnings (Trailing)

-8.78

Price/Sales (Trailing)

417.83

Price/Free Cashflow

-11.64

REPL Price/Sales (Trailing)

REPL Profitability

Return on Equity

-38.2%

Return on Assets

-33.65%

Free Cashflow Yield

-8.59%

REPL Fundamentals

REPL Revenue

Revenue (TTM)

3.1M

Revenue Y/Y

-20.83%

Revenue Q/Q

-32.55%

REPL Earnings

Earnings (TTM)

-146.7M

Earnings Y/Y

-46.61%

Earnings Q/Q

-2.01%

Price Action

52 Week Range

13.0529.41
(Low)(High)

Last 7 days

-5.6%

Last 30 days

-3.4%

Last 90 days

43.3%

Trailing 12 Months

39.6%

REPL Financial Health

Current Ratio

16.12

REPL Investor Care

Buy Backs (1Y)

4.50%

Diluted EPS (TTM)

-2.74

Peers (Alternatives to Replimune Group)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
135.3B
26.3B
-2.97% 16.81%
19.8
5.14
2.18% 21.86%
105.0B
27.1B
-0.99% 30.15%
31.49
3.87
-1.26% -54.91%
73.3B
21.4B
7.28% 27.41%
6.23
3.43
80.80% 66.62%
41.9B
10.4B
5.85% 32.49%
14.62
4.04
-6.64% 85.32%
10.4B
1.4B
-8.79% 49.41%
178.74
7.49
29.86% -86.92%
MID-CAP
3.9B
-
18.31% 0.06%
-12.88
32.03
-41.50% -1123.42%
3.2B
-
23.33% -24.11%
-10.12
59.51
215916.67% 21.41%
SMALL-CAP
1.7B
432.8M
17.41% -21.00%
20.97
3.87
1042.97% 128.67%
1.4B
-
35.16% 1.79%
-2.74
20.84
745.14% 12.80%
1.3B
3.1M
-3.43% 39.57%
-8.78
417.83
7.05% -46.74%
886.0M
1.8B
24.61% -84.52%
-0.67
0.48
53.41% -22.97%
574.9M
69.0M
-39.96% -83.45%
-1.96
8.33
26.22% -49.52%
565.8M
112.1M
28.78% -35.14%
-3.18
5.05
3.26% 1.99%
142.4M
-
42.67% -74.19%
-1.36
418.24
-71.03% -64.56%
6.7M
-
67.66% -93.12%
-0.11
3.21
0.51% -141.69%

Financials for Replimune Group

Income Statement (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-4.7%3,0823,2333,1703,0622,879
Operating Expenses9.4%144,141131,809118,314108,51099,087
  S&GA Expenses8.2%44,74041,34038,76934,47630,084
  R&D Expenses9.9%99,40190,46979,54574,03469,003
Interest Expenses-100.0%01.00248--
Net Income-10.3%-146,725.00-133,023.00-118,036.00-107,884.00-99,993.00
Net Income Margin-15.7%-47.61*-41.13*-37.22*-35.22*-
Free Cahsflow-10.2%-110,651.00-100,434.00-84,516.00-77,705.00-
* denotes actual numbers (not divided by Thousands)
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-5.1%436459461485503
  Current Assets-5.6%379402404428444
    Cash Equivalents-20.8%89112106132162
  Net PPE-4.3%88877
Liabilities5.8%5249504846
  Current Liabilities15.9%2420211817
Shareholder's Equity-6.4%384410411438457
  Retained Earnings-12.2%-396.60-353.50-311.20-279.51-249.83
  Additional Paid-In Capital1.9%778763723717707
Shares Outstanding0.9%5049474752
Float-620----
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-10.5%-107.57-97.32-82.18-75.75-70.39
  Share Based Compensation2.7%2625242219
Cashflow From Investing47.2%-12.39-23.48-1.81-123.75-78.91
Cashflow From Financing16.5%443877265

Risks for REPL

What is the probability of a big loss on REPL?

95.4%


Probability that Replimune Group stock will be more than 20% underwater in next one year

94.1%


Probability that Replimune Group stock will be more than 30% underwater in next one year.

88.7%


Probability that Replimune Group stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does REPL drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Replimune Group was unfortunately bought at previous high price.

Drawdowns

Returns for REPL

Cumulative Returns on REPL

13.1%


3-Year Cumulative Returns

Which funds bought or sold REPL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-01-26
STRS OHIO
unchanged
-
42,000
116,000
-%
2023-01-24
Moody Aldrich Partners LLC
new
-
2,487,090
2,487,090
0.50%
2023-01-20
HARBOR CAPITAL ADVISORS, INC.
reduced
-2.11
259,059
736,059
0.71%
2023-01-13
Allworth Financial LP
unchanged
-
354
354
-%
2023-01-12
Hennion & Walsh Asset Management, Inc.
added
14.47
427,000
960,000
0.06%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
13.22
68,000
641,000
-%
2022-11-16
BNP PARIBAS ARBITRAGE, SNC
added
538.73
593,264
704,979
-%
2022-11-15
STATE STREET CORP
reduced
-12.11
-3,801,000
25,072,000
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
sold off
-
-
-
-%
2022-11-15
ALLIANCEBERNSTEIN L.P.
unchanged
-
-6,000
532,000
-%

1–10 of 47

Latest Funds Activity

Are funds buying REPL calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own REPL
No. of Funds

Replimune Group News

Invest Chronicle

Replimune Group Inc. (REPL): What Top Wall Street Players are ....

Invest Chronicle,
38 hours ago

Marketscreener.com

Seeking Alpha

Revisiting Replimune (NASDAQ:REPL).

Seeking Alpha,
50 days ago

Yahoo Finance

Schedule 13G FIlings of Replimune Group

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Nov 18, 2022
redmile group, llc
9.9%
5,165,131
SC 13G/A
Sep 14, 2022
atlas venture fund x, l.p.
4.4%
2,164,037
SC 13D/A
Feb 14, 2022
redmile group, llc
9.9%
4,775,461
SC 13G/A
Feb 14, 2022
omega fund iv, l.p.
10.6%
5,012,052
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
12.5%
5,868,638
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Jul 12, 2021
price t rowe associates inc /md/
10.8%
5,069,450
SC 13G/A
Feb 16, 2021
bain capital life sciences fund, l.p.
0%
0
SC 13G/A
Feb 16, 2021
price t rowe associates inc /md/
5.7%
2,625,691
SC 13G
Feb 16, 2021
forbion capital fund iii cooperatief u.a.
11.13%
5,115,121
SC 13G/A

REPL Fair Value

Recent SEC filings of Replimune Group

View All Filings
Date Filed Form Type Document
Jan 04, 2023
8-K
Current Report
Dec 13, 2022
4
Insider Trading
Dec 12, 2022
424B5
Prospectus Filed
Dec 12, 2022
8-K
Current Report
Dec 07, 2022
8-K
Current Report
Dec 07, 2022
424B5
Prospectus Filed
Dec 06, 2022
SC 13D/A
13D - Major Acquisition
Dec 05, 2022
3
Insider Trading
Dec 05, 2022
4
Insider Trading
Nov 18, 2022
SC 13G/A
Major Ownership Report

Latest Insider Trading transactions for REPL

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-12-09
Esposito Pamela
acquired
15,150
1.01
15,000
chief business officer
2022-12-09
Esposito Pamela
sold
-375,450
25.03
-15,000
chief business officer
2022-12-01
Xynos Konstantinos
acquired
-
-
17,500
chief medical officer
2022-05-16
Patel Sushil
sold
-155,923
14.59
-10,687
chief commercial officer
2022-05-16
Esposito Pamela
sold
-51,167.1
14.59
-3,507
chief business officer
2022-05-16
Love Colin
sold
-92,267.2
14.59
-6,324
chief operating officer
2022-05-16
Lewis Tanya
sold
-79,851.1
14.59
-5,473
chief dev. op officer
2022-05-16
Coffin Robert
sold
-83,702.8
14.59
-5,737
president & chief r&d officer
2022-05-16
Astley-Sparke Philip
sold
-140,531
14.59
-9,632
chief executive officer
2022-05-16
Franchi Jean M.
sold
-50,131.2
14.59
-3,436
chief financial officer

1–10 of 50

Philip Astley-Sparke
150
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

REPL Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating expenses:    
Research and development$ 28,834$ 19,902$ 58,312$ 38,456
Selling, general and administrative12,7459,34524,14318,172
Total operating expenses41,57929,24782,45556,628
Loss from operations(41,579)(29,247)(82,455)(56,628)
Other income (expense):    
Research and development incentives5747251,4251,513
Investment income1,112801,455172
Interest expense on finance lease liability(550)(557)(1,102)(1,115)
Other (expense) income(2,659)(356)(4,678)(608)
Total other (expense) income, net(1,523)(108)(2,900)(38)
Net loss$ (43,102)$ (29,355)$ (85,355)$ (56,666)
Net loss per share attributable to common stockholders, basic (in dollars per share)$ (0.79)$ (0.56)$ (1.57)$ (1.09)
Net loss per share attributable to common stockholders, diluted (in dollars per share)$ (0.79)$ (0.56)$ (1.57)$ (1.09)
Weighted average common shares outstanding, basic (in shares)54,770,29152,081,32554,492,39551,962,795
Weighted average common shares outstanding, diluted (in shares)54,770,29152,081,32554,492,39551,962,795

REPL Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Mar. 31, 2022
Current assets:  
Cash and cash equivalents$ 88,930$ 105,948
Short-term investments282,890289,707
Research and development incentives receivable2,5893,055
Prepaid expenses and other current assets4,9815,267
Total current assets379,390403,977
Property, plant and equipment, net7,9107,933
Research and development incentives receivable, non-current1,2960
Restricted cash1,6361,636
Right-to-use asset - operating leases4,9845,552
Right-to-use asset - financing leases40,87942,094
Total assets436,095461,192
Current liabilities:  
Accounts payable3,9963,732
Accrued expenses and other current liabilities15,93913,392
Operating lease liabilities, current1,0021,070
Financing lease liabilities, current2,6002,562
Total current liabilities23,53720,756
Operating lease liabilities, non-current4,2804,801
Financing lease liabilities, non-current24,20624,406
Total liabilities52,02349,963
Commitments and contingencies (Note 11)
Stockholders' equity  
Common stock, $0.001 par value; 150,000,000 shares authorized as of September 30, 2022 and March 31, 2022; 49,739,407 and 47,338,660 shares issued and outstanding as of September 30, 2022 and March 31, 2022, respectively5047
Additional paid-in capital777,650723,359
Accumulated deficit(396,559)(311,204)
Accumulated other comprehensive income (loss)2,931(973)
Total stockholders' equity384,072411,229
Total liabilities and stockholders' equity$ 436,095$ 461,192